Singapore, Oct. 29 -- Japan-based Renalys Pharma and Chugai Pharmaceutical have announced a definitive stock purchase agreement, under which Chugai will acquire Renalys. Renalys is advancing sparsentan in Japan; the medicine was initially developed by Travere Therapeutics, Inc. and is approved in the United States and Europe for the treatment of IgA nephropathy.
As part of the transaction,Chugai will gain exclusive rights to develop and commercialise sparsentan in Japan, South Korea, and Taiwan.
Founded to close Asia's persistent "drug lag," Renalys develops innovative therapies for chronic kidney disease across Japan and the region. The company has completed primary endpoint data collection in its Japan Phase III clinical trial ofsparsen...